




Fig. 1A






Fig. 1B


MMAE – microtubule inhibitor



SN38 and PNU159682– topoisomerase inhibitors



PBD – alkylating agent



Dasatinib – protein kinase inhibitor








Fig. 2A

Cleavable linkers**MA-PEG4-VC-PAB-DMAE****Mal-C2-Gly3-EDA****PEG8-triazole-PABC-peptide-MC****Non-cleavable linkers****MAC glucuronide****Fig. 2B**

SUBSTITUTE SHEET (RULE 26)




Fig. 2C




Fig. 3A






Fig. 3B

SN38-MES-ADC



PNU-MES-ADC




Fig. 3C




Fig. 4A





Fig. 4B

Human mesothelioma PDx PXF1118

no Ab

CA125

antigen



Human NSCLC PDx # LXFA983

no Ab

CA125

antigen




Fig. 4C




Fig. 4D




Fig. 4E




Fig. 5




Fig. 6A




Fig. 6B

MES-BSP in vivo study design





Fig. 7